Bal Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Bal Pharma has a total shareholder equity of ₹632.0M and total debt of ₹1.4B, which brings its debt-to-equity ratio to 223.2%. Its total assets and total liabilities are ₹3.3B and ₹2.7B respectively. Bal Pharma's EBIT is ₹215.3M making its interest coverage ratio 1.6. It has cash and short-term investments of ₹83.8M.
Key information
223.2%
Debt to equity ratio
₹1.41b
Debt
| Interest coverage ratio | 1.6x |
| Cash | ₹83.79m |
| Equity | ₹632.03m |
| Total liabilities | ₹2.67b |
| Total assets | ₹3.30b |
Recent financial health updates
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14
Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Recent updates
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00
Aug 28Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 14Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 17Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00
Jul 31Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?
Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?
Aug 10Financial Position Analysis
Short Term Liabilities: BALPHARMA's short term assets (₹2.4B) exceed its short term liabilities (₹2.3B).
Long Term Liabilities: BALPHARMA's short term assets (₹2.4B) exceed its long term liabilities (₹380.5M).
Debt to Equity History and Analysis
Debt Level: BALPHARMA's net debt to equity ratio (209.9%) is considered high.
Reducing Debt: BALPHARMA's debt to equity ratio has increased from 207.1% to 223.2% over the past 5 years.
Debt Coverage: BALPHARMA's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BALPHARMA's interest payments on its debt are not well covered by EBIT (1.6x coverage).